Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in regularly transfused pediatric pyruvate kinase deficiency
2021-003265-36Phase 3Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mitapivat in pyruvate kinase deficiency (PKD) (3 arms), sponsored by Agios Pharmaceuticals. Primary endpoint: Transfusion reduction response. Started Nov 2021; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on 2021-003265-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003265-36.